Search

Your search keyword '"A. Russell"' showing total 4,968 results

Search Constraints

Start Over You searched for: Author "A. Russell" Remove constraint Author: "A. Russell" Journal blood Remove constraint Journal: blood
4,968 results on '"A. Russell"'

Search Results

1. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels

2. Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target

3. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML

4. An LGR6 frameshift variant abrogates receptor expression on select leukocyte subsets and is associated with viral infections

5. Whole-genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles

7. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

8. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study

10. Overlapping features of therapy-related and de novo NPM1-mutated AML

11. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

12. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

13. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

14. T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome

16. SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

19. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma

21. Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review

22. SRSF2 Is Essential For Hematopoiesis and Its Mutations Dysregulate Alternative RNA Splicing In MDS

24. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

25. Postinduction molecular MRD identifies patients with NPM1AML who benefit from allogeneic transplant in first remission

26. Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis

27. Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi

28. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

29. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

32. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment

33. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

35. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

36. The ability to cross the blood–cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts

38. A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

41. FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

42. Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

44. In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

45. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

50. T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome

Catalog

Books, media, physical & digital resources